Overview
- By a 7–4 majority, the Court kept the ANS list as a reference and confirmed that off‑list treatments may be ordered only if five cumulative requirements are met.
- The criteria are: qualified prescription, no express ANS denial or pending inclusion review, no adequate alternative in the rol, robust scientific evidence of efficacy and safety, and Anvisa registration.
- Judges must verify prior request to the operator, consult NATJUS, avoid rulings based solely on a patient’s medical report, and notify ANS if a provisional order is granted.
- The minority of four justices agreed the law is valid but argued that defining exceptions belongs to the health regulator ANS rather than the Supreme Court.
- Consumer advocates such as Idec warn the stricter test will hinder access for beneficiaries, while industry groups say clearer rules could curb litigation and support sector sustainability.